spacer
home > pmps > our clients
OUR CLIENTS

The magazine’s readership is 10,500, targeted directly at strategic decision-makers within pharmaceutical companies and their contract partners across Europe, North America and the rest of the world. Combining editorial integrity with a broad spectrum of topic areas, the magazine has proved an effective advertising medium for organisations wishing to target this dynamic market.

Advertisers in the last issue of PMPS were:

Almac Group

Aesica Pharmaceuticals

American Airlines Cargo

Austrian Cargo

BENEO-Palatinit GmbH

Brecon Pharmaceuticals

Burkert

Canon Communications LLC

Capsugel

CBI

Cryo Store bv

CSafe, LLC

Dales Pharmaceuticals

DSM

ELPRO-BUCHS AG

Emball-iso

Emirates SkyCargo

Enestia Belgium nv/sa

Envirotainer AB

Gate2Tech

 Geodis Wilson

Gerhard Schubert Gmbh

Grifols Partnership

Health Protection Agency

Helvoet Pharma

HPT Hochwertige Pharmatechnik Gmbh & Co KG

Lomapharm

Lyofal

Meadwestvaco

Multisorb Technologies

Nuova Ompi

Nycomed Global Contract Manufacturing

Palletways

Patheon

Pharmintech - Ipack-Ima Spa

Piramal Healthcare

Promens Medical Packaging A/S

R5 Pharmaceuticals Ltd

Rohrer AG

Roquette

Rovi Contract Manufacturing

SCA Cool Logistics

Sensitech

Sigpack Systems AG

SMi Group Ltd

Sofrigam

Solvay Injectables

Stelmi SA

UBM International Media

Uhlmann UK Ltd

VIFOR Pharma

Vindon Scientific Limited

Weiler Engineering, Inc

West Pharmaceutical Services, Inc

 

 

 

 

spacer
Edited by
Robert Harris
Chief Technical Officer at Juniper Pharma Services
Published quarterly in
February, May,
August and November
 
Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 
News and Press Releases

Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound


More info >>

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement